Travere Therapeutics (TVTX) is down -6.6%, or -$1.79 to $25.52.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics price target raised to $35 from $27 at Wells Fargo
- Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
- Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
- AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies
- FDA reversing course on adcomm should reassure Travere investors, says BofA